A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
Guselkumab, a human IgG1 monoclonal antibody that blocks interleukin-23, has been evaluated in one Phase 2 and two Phase 3 trials in patients with moderate-to-severe psoriasis, in which disease severity was assessed using Psoriasis Area and Severity Index (PASI) and Investigator’s Global Assessment (IGA) scores. Through the application of landmark and longitudinal exposure–response (E–R) modeling analyses, we sought to predict the guselkumab dose–response (D–R) relationship using data from 1459 patients who participated in these trials. A recently developed novel latent-variable Type I Indirect Response joint model was applied to PASI75/90/100 and IGA response thresholds, with placebo effect empirically modeled. An effect of body weight on E–R, independent of pharmacokinetics, was identified. Thorough landmark analyses also were implemented using the same dataset. The E–R models were combined with a population pharmacokinetic model to generate D–R predictions. The relative merits of longitudinal and landmark analysis also are discussed. The results provide a comprehensive and robust evaluation of the D–R relationship.
KeywordsExposure–response modeling NONMEM Ordered categorical endpoints Joint modeling Latent variable IDR modeling Clinical drug development
The authors thank Michelle L. Perate MS, a professional medical writer funded by Janssen Scientific Affairs., LLC, for editorial support.
- 5.Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76(3):405–417. https://doi.org/10.1016/j.jaad.2016.11.041 CrossRefPubMedGoogle Scholar
- 6.Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76(3):418–431. https://doi.org/10.1016/j.jaad.2016.11.042 CrossRefPubMedGoogle Scholar
- 7.Hu C, Randazzo B, Sharma A, Zhou H (2017) Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. J Pharmacokinet Pharmacodyn 44(5):437–448. https://doi.org/10.1007/s10928-017-9531-3 CrossRefPubMedGoogle Scholar
- 8.Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237–260. https://doi.org/10.1007/s10928-011-9191-7 CrossRefPubMedGoogle Scholar
- 19.Yao Z, Hu C, Zhu Y, Xu Z, Randazzo B, Wasfi Y, Chen Y, Sharma A, Zhou H (2018) Population pharmacokinetic modeling of guselkumab, a human IgG1λ monoclonal antibody targeting IL-23, in patients with moderate-to-severe plaque psoriasis. J Clin Pharmacol. https://doi.org/10.1002/jcph.1063 PubMedCentralCrossRefPubMedGoogle Scholar
- 25.Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user’s guides (1989–2009). Icon Development Solutions, Ellicott CityGoogle Scholar
- 26.Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks. http://www.page-meeting.org/?abstract=1434. Accessed Jan 3 2018
- 28.Hu C, Szapary P, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data, model validation: application to exposure-response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodynam 38(2):237–260. https://doi.org/10.1007/s10928-011-9191-7 CrossRefGoogle Scholar